Allison Bratzel
Stock Analyst at Piper Sandler
(0)
# 2664
Out of 5,311 analysts
38
Total ratings
42.86%
Success rate
8.14%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
RARE Ultragenyx Pharmaceutical | Maintains: Overweight | 140 115 | 32.91 | 249.44% | 1 | Mar 17, 2025 | |
AKBA Akebia Therapeutics | Maintains: Overweight | 4 6 | 1.58 | 279.75% | 1 | Mar 14, 2025 | |
INZY Inozyme Pharma | Maintains: Overweight | 30 23 | 0.89 | 2484.27% | 1 | Mar 11, 2025 | |
ENGN enGene Holdings | Initiates Coverage On: Overweight | 26 | 4 | 550% | 1 | Feb 18, 2025 | |
ARGX argenx | Maintains: Overweight | 620 725 | 549.32 | 31.98% | 13 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 12 22 | 13.71 | 60.47% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 23 | 16.34 | 40.76% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 62 | 26.85 | 130.91% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 42 | 26.37 | 59.27% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 22 | 9.62 | 128.69% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 4 | 1.51 | 164.9% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 8 20 | 2.7 | 640.74% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 20 | 2.06 | 870.87% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 23 25 | n/a | n/a | 1 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 44 | 6.97 | 531.28% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 | 55.42 | 80.44% | 2 | Feb 8, 2023 |